Results from the HARMONi-A study showed that ivonescimab, a tetravalent bispecific antibody targeting PD-1 and VEGF-A, plus chemotherapy significantly improved median PFS over chemotherapy alone (7.1 vs. 4.8 months) among NSCLC patients with failure in EGFR-TKIs therapy (60). Here, EGFR is linked to non-small cell lung carcinoma.